Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Beta-Thalassemia Associated Anemia
Last updated:
October 18, 2022
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
High-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, in adult patients
Last updated:
October 7, 2022
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
High-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, in adult patients
Last updated:
October 7, 2022
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Non-small cell lung cancer (NSCLC) adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
Last updated:
October 7, 2022
Tafinlar/Mekinist (dabrafenib/trametinib)
Status:
Concluded without agreement
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation in patients who have not received any prior anti-cancer therapy for metastatic disease
Last updated:
September 30, 2022
Bryhali (halobetasol propionate)
Status:
Concluded with an LOI
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Corticosteroid-Responsive Dermatoses and The Topical Treatment of Plaque Psoriasis
Last updated:
September 27, 2022
Insulin pumps and pump supplies (Insulin pumps and pump supplies)
Status:
Concluded with an LOI
Manufacturer:
Insulet Canada Corporation
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated:
September 20, 2022
Luxturna (voretigene neparvovec)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Vision loss, inherited retinal dystrophy
Last updated:
September 16, 2022
Status:
Concluded with an LOI
Manufacturer:
Seagen Canada Inc.
Indication:
Breast cancer, locally advanced unresectable or metastatic, HER2-positive, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination (in combination with trastuzumab and capecitabine)
Last updated:
September 14, 2022
Status:
Negotiations were not pursued
Manufacturer:
BeiGene, Ltd.
Indication:
Mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
Last updated:
September 7, 2022